# High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

> **NCT01965275** · PHASE2 · UNKNOWN · sponsor: **Anhui Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Self Efficacy
- Drug Toxicity

## Interventions

- **DRUG:** Erlotinib or Gefitinib

## Key facts

- **NCT ID:** NCT01965275
- **Lead sponsor:** Anhui Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01965275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01965275, "High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01965275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*